BioSpace News Archive

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today highlighted the company’s role in the manufacturing of Veklury ® (remdesivir), Gilead Sciences’ antiviral drug for the treatment of patients with COVID-19 requiring hospitalization. Veklury is formulated with Ligand’s Captisol ® technology. Approved yesterday by the U.S. Food and Drug Administration, Veklury is the first and only approved COVID-19 treatment in the Un

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) will hold its 2020 Third Quarter Earnings Conference Call on Thursday, November 5, 2020 at 8:30 a.m. EST.

Synairgen’s SNG001 among the many potential treatments and vaccines to be delivered via Aerogen’s aerosol drug delivery system Adds to the thousands of COVID-19 patients already safely and effectively treated with Aerogen’s Solo aerosol drug delivery system in the intensive care unit 1 Aerogen technology is featured in guidelines and papers on the treatment of COVID-19 patients across the globe 2 , 3 , 4

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a pioneer in the development of a universal flu vaccine designed to provide protection against current, future, seasonal and pandemic influenza, today announced topline data from the Company’s pivotal, phase 3 clinical trial of M-001 as a standalone universal flu vaccine candidate.

- Jardiance (empagliflozin) reduced risk for the composite endpoint of cardiovascular death and hospitalization for heart failure, as well as serious adverse kidney outcomes, in adults with or without chronic kidney disease at baseline. The trial included people with and without diabetes - Sub-analysis findings from the EMPEROR-Reduced phase III trial were presented at the American Society of Nephrology Kidney Week 2020

During the 2020 ASTRO Annual Meeting, taking place online October 23-29, Sun Nuclear is highlighting a range of solutions clinics can leverage to ensure continuity for their Quality Management programs.

As we continue to address the health, social, and economic impacts of COVID-19, the Government of Canada is actively pursuing the purchase and development of vaccines, treatments, and related supplies to protect Canadians from the virus and support our recovery from the pandemic

Leading emergency medicine researchers will be on hand for the American College of Emergency Physicians (ACEP) Research Forum, part of ACEP20, the world’s largest emergency medicine conference

INTERLINK-1 represents first Phase 3 study examining IO approach in R/M SCCHN patients who have been treatedwith a platinum-based therapy and PD-(L)1 inhibitor

New test enables “in your own lab” sample-to-report workflow that detects and quantifies >6,000 microbial strains in under 30 hours.